News

Filter

Current filters:

None

7939 to 7948 of 96157 results

Roche extends Illumina takeover deadline

28-02-2012

Roche has extended its $5.7 billion hostile takeover offer for genetic sequencing specialist Illumina…

HomeIlluminaMergers & AcquisitionsPharmaceuticalRoche

GSK inks $300m rare diseases alliance with Angiochem

28-02-2012

GlaxoSmithKline has forged an R&D alliance with Montreal, Canada-based Angiochem that will focus on the…

AngiochemCerezymeGenzymeGSKNeurologicalPharmaceuticalRare diseasesShireVpriv

New data support efficacy of Astellas' mirabegron for overactive bladder

28-02-2012

Astellas Pharma has reported the results of three separate clinical trials which further support the…

Astellas PharmaBetanisGenito-urinaryHomemirabegronPharmaceuticalVESIcare

Takeda's GPR40 agonist for diabetes promising in Ph II trial

28-02-2012

A Phase II trial of Takeda's GPR40 agonist TAK-875 published in The Lancet has found that the drug is…

DiabetesHomepeginesatidePharmaceuticalTAK-875Takeda Pharmaceuticals

GSK boss accuses UK government of blocking new drugs to save money

27-02-2012

The chief executive of the UK’s largest pharmaceutical company, GlaxoSmithKline (LSE: GSK) has accused…

EuropeGlaxoSmithKlineMarkets & MarketingPharmaceuticalPricingRegulation

Greek pharma sector bemoans accumulation of debts

27-02-2012

The Greek pharmaceutical industry association, the SFEE, says that pharmaceutical companies may go out…

EuropeFinancialHealthcarePharmaceuticalPolitics

No proof of added benefit for GlaxoSmithKline’s Trobalt, says IQWiG

27-02-2012

In another warning to drugmakers trying to get approval of new drugs under Germany’s AMNOG reform…

EuropeGlaxoSmithKlineNeurologicalPharmaceuticalPricingRegulationTrobalt

Forest Labs get EU appro for Colobreathe

27-02-2012

US drugmaker Forest Laboratories (NYSE: FRX) said on Friday that the European Medicines Agency has approved…

ColoBreatheColomycinEuropeForest LaboratoriesPharmaceuticalRare diseasesRegulation

7939 to 7948 of 96157 results

Back to top